News

Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call

MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…

1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 year ago

Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

Beauty Pioneer Kendra Bracken-Ferguson Appointed CEO of Carmell Corporation To Champion a Technological Revolution in Regenerative Skincare and Haircare and Build Beauty…

1 year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis…

1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary…

1 year ago

Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Provides IDE Submission Status Update The…

1 year ago

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:…

1 year ago

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go…

1 year ago

iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography

Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite ExpansionNASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C.,…

1 year ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next…

1 year ago